QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silk-road-medical-q2-eps-042-misses-038-estimate-sales-5124m-beat-4960m-estimate

Silk Road Medical (NASDAQ:SILK) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $...

 stifel-downgrades-silk-road-medical-to-hold-raises-price-target-to-275

Stifel analyst Rick Wise downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and raises the price target from $23 to...

 argus-research-downgrades-silk-road-medical-to-sell

Argus Research analyst Steve Silver downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Sell.

 lake-street-downgrades-silk-road-medical-to-hold-lowers-price-target-to-275

Lake Street analyst Frank Takkinen downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and lowers the price target f...

Core News & Articles

- SEC Filing

 boston-scientific-adds-stroke-prevention-to-vascular-portfolio-via-silk-road-medicals-13b-deal

Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR sy...

Core News & Articles

Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Sil...

Core News & Articles

The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical's...

 jp-morgan-maintains-neutral-on-silk-road-medical-raises-price-target-to-21

JP Morgan analyst Robbie Marcus maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from $1...

 piper-sandler-maintains-neutral-on-silk-road-medical-raises-price-target-to-20

Piper Sandler analyst Adam Maeder maintains Silk Road Medical (NASDAQ:SILK) with a Neutral and raises the price target from ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION